• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Tema Launches Healthcare AI ETF (HLTH)

    7/21/26 12:00:00 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $HLTH alert in real time by email

    HLTH is the first pure-play ETF focused on AI’s transformation of healthcare.

    Tema ETFs ("Tema"), a leader in institutional-quality and actively managed exchange-traded funds, today announced the launch of the Tema Healthcare AI ETF (HLTH).

    HLTH was developed to invest in one of AI’s largest and most consequential applications: improving healthcare. U.S. healthcare spending is forecast to approach $9 trillion by 2034, representing more than 20% of GDP.1 Yet healthcare accounted for just 8.9% of the S&P 500 as of June 30,2 leaving AI’s potential to elevate the sector underappreciated by the market.

    That potential is rapidly moving from research to implementation. DeepMind’s AlphaFold, an AI model that predicts protein structures, won the 2024 Nobel Prize in Chemistry and is already used by more than 2 million researchers,3 demonstrating how quickly a scientific breakthrough can become a widely adopted research tool. Anthropic has said AI could compress a century of biological progress into a decade, while healthcare and biopharma together represent the third-largest category of global private AI investment.

    As the AI investment cycle broadens beyond the semiconductor-led infrastructure buildout, healthcare stands as one of the largest markets for adoption. HLTH offers a pure-play way to invest in that shift, targeting companies at the leading edge of drug discovery, diagnostics, clinical applications such as robotics, and technologies that improve patient care.

    Healthcare innovation is complex, highly specialized, and marked by significant scientific and clinical risk, which Tema believes warrants an expert-led approach. HLTH is managed by Dr. David Song, MD, PhD, CFA, a Yale and Penn-trained physician with more than two decades of healthcare investing experience.

    "AI has the potential to improve nearly every aspect of healthcare, from research and diagnosis to treatment and care delivery," said Dr. David Song, Investment Partner and Portfolio Manager of HLTH. "In drug development, it can help researchers identify better candidates faster and improve the odds of clinical success. In clinical settings, it can enable earlier detection, greater precision, and more efficient care. We believe navigating these opportunities requires expertise and an active approach to identifying advances that can deliver better outcomes for patients, providers, and investors alike."

    Fund Facts

    Ticker

    HLTH

    Exchange

    NASDAQ

    CUSIP

    87975E768

    Gross Expense Ratio

    0.75%

    Listing Date

    July 21, 2026

    Fund Webpage

    temaetfs.com/HLTH

    About Tema ETFs

    Tema builds institutional-quality ETF solutions for a range of market environments, spanning high-conviction growth opportunities, durable core exposures, and alternatives. Founded in 2022, Tema is led by veterans of the ETF and global asset management industry, and backed by Index Ventures, Accel Partners, Zinal Growth, and over a dozen financial services CEOs and fintech founders.

    HLTH Top 10 Holdings (as of Jul 21)

    Security Name

    Weight

    10X GENOMICS INC

    5.40%

    CYTOKINETICS INC

    5.19%

    ILLUMINA INC

    4.96%

    INTUITIVE SURGICAL INC

    4.60%

    VERTEX PHARMACEUTICALS INC

    4.50%

    REVOLUTION MEDICINES INC

    4.48%

    TWIST BIOSCIENCE CORP

    4.06%

    COGENT BIOSCIENCES INC

    4.01%

    DEXCOM INC

    4.01%

    NATERA INC

    3.96%

    As of Jul 21, 2026. For all current holdings, visit the HLTH fund webpage.

    Sourcing

    1 Centers of Medicare & Medicaid Services, NHE Fact Sheet, as of Jul 2026

    2 Bloomberg, Jun 2026

    3 AI Magazine, "AlphaFold 2: The AI System That Won Google a Nobel Prize," Oct 2024

    Disclosures

    Institutional-quality qualification is premised on the >90% estimated institutional adoption of Tema's funds to date as of Jul 21, 2026 and the institutional background and track record of Tema's investment team.

    Carefully consider the Fund's investment objectives, risk factors, charges and expenses before investing. This and additional information can be found in the Fund's prospectus or summary prospectus, which may be obtained by visiting www.temaetfs.com. Read the prospectus carefully before investing.

    Investing involves risk including possible loss of principal. There is no guarantee the fund's investment strategy will be successful.

    Sector Focus Risk: The Fund may invest a significant portion of its assets in one or more sectors and thus will be more susceptible to the risks affecting those sectors than funds that have more diversified holdings across a number of sectors. The Fund anticipates that it may be subject to some or all of the risks described below.

    Healthcare Sector Risk: To the extent the Fund focuses on the healthcare sector, the Fund may be more susceptible to the particular risks that may affect companies in the healthcare sector than if it were invested in a wider variety of companies in unrelated sectors. The profitability of companies in the healthcare sector may be adversely affected by the following factors, among others: extensive government regulations, restrictions on government reimbursement for medical expenses, rising costs of medical products and services, pricing pressure, an increased emphasis on outpatient services, changes in the demand for medical products and services, a limited number of products, industry innovation, changes in technologies and other market developments. The expiration of a company’s patents may adversely affect that company’s profitability. Healthcare companies are subject to competitive forces that may make it difficult to raise prices and, in fact, may result in price discounting. Many new products in the healthcare sector may be subject to regulatory approvals. The process of obtaining such approvals may be long and costly, and such efforts ultimately may be unsuccessful. Companies in the healthcare sector may be thinly capitalized and may be susceptible to product obsolescence.

    Information Technology Sector Risk: Information technology companies face intense competition, both domestically and internationally, which may have an adverse effect on their profit margins. Like other technology companies, information technology companies may have limited product lines, markets, financial resources or personnel. Companies in the information technology sector are heavily dependent on patent and intellectual property rights. The loss or impairment of any of these rights may adversely affect the profitability of these companies or the Fund’s performance.

    Tema ETFs LLC serves as the investment adviser to Tema Healthcare AI ETF (the "Fund"), and Tidal Investments LLC serves as a sub-adviser to the Fund. The Fund is distributed by Vigilant Distributors, LLC, which is not affiliated with Tema ETFs LLC nor Tidal Investments LLC. Check the background of Vigilant Distributors, LLC on FINRA’s BrokerCheck.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260721480281/en/

    Media Contact

    Steve Munroe

    Tema ETFs

    PR@temaetfs.com

    Get the next $HLTH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HLTH

    DatePrice TargetRatingAnalyst
    3/14/2024Buy → Neutral
    BTIG Research
    10/19/2021$18.00Buy
    BTIG Research
    10/19/2021$12.00Equal-Weight
    Morgan Stanley
    10/19/2021$19.00Buy
    Goldman Sachs
    10/19/2021$14.00Outperform
    Cowen & Co.
    More analyst ratings

    $HLTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Javed Aasim covered exercise/tax liability with 13,327 shares, decreasing direct ownership by 1% to 998,004 units (SEC Form 4) (Amendment)

    4/A - Cue Health Inc. (0001628945) (Issuer)

    5/21/24 6:29:25 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Sever Clint covered exercise/tax liability with 20,456 shares, decreasing direct ownership by 0.46% to 4,379,914 units (SEC Form 4)

    4 - Cue Health Inc. (0001628945) (Issuer)

    3/27/24 7:29:01 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Pollard Randall E. covered exercise/tax liability with 7,304 shares, decreasing direct ownership by 1% to 503,202 units (SEC Form 4)

    4 - Cue Health Inc. (0001628945) (Issuer)

    3/7/24 8:45:08 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $HLTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tema Launches Healthcare AI ETF (HLTH)

    HLTH is the first pure-play ETF focused on AI’s transformation of healthcare. Tema ETFs ("Tema"), a leader in institutional-quality and actively managed exchange-traded funds, today announced the launch of the Tema Healthcare AI ETF (HLTH). HLTH was developed to invest in one of AI’s largest and most consequential applications: improving healthcare. U.S. healthcare spending is forecast to approach $9 trillion by 2034, representing more than 20% of GDP.1 Yet healthcare accounted for just 8.9% of the S&P 500 as of June 30,2 leaving AI’s potential to elevate the sector underappreciated by the market. That potential is rapidly moving from research to implementation. DeepMind’s AlphaFold,

    7/21/26 12:00:00 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Made Scientific Strengthens Board to Support Scale-Up and Commercial Readiness in Cell Therapy Manufacturing

    PRINCETON, N.J., April 30, 2026 /PRNewswire/ -- Made Scientific, a U.S.-based contract development and manufacturing organization (CDMO) specializing in cell therapies, today announced the continued build-out of its Board of Directors, including the appointment of Ted Dolan and Soyoung Park. They join Jin Pyun, Harry S. Rathore, Ph.D., and Yonghoon Kim, alongside Chairman and CEO Syed T. Husain, as part of a deliberate effort to align the company's governance with its next phase of growth. Over the past year, Made Scientific has assembled a Board with deep experience spanning CD

    4/30/26 11:47:00 AM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Cue Health to Pursue Wind Down of the Business

    Cue Health Inc. ("Cue" or the "Company") (NASDAQ:HLTH), a healthcare technology company, today announced the Company has filed voluntary petitions under Chapter 7 of the U.S. Bankruptcy Code in the District of Delaware to pursue a wind down of its business. Cue has been working diligently to strengthen the Company's financial foundation, including taking a number of actions to reduce costs and improve operational efficiency. Cue also undertook an extensive process to locate additional financing or effect a strategic transaction. Despite its best efforts and after a comprehensive review, Cue's Board of Directors in consultation with the Company's advisors, has concluded that it is in the b

    5/28/24 4:31:00 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $HLTH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

    For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

    6/6/23 3:04:14 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $HLTH
    Leadership Updates

    Live Leadership Updates

    View All

    $HLTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Made Scientific Strengthens Board to Support Scale-Up and Commercial Readiness in Cell Therapy Manufacturing

    PRINCETON, N.J., April 30, 2026 /PRNewswire/ -- Made Scientific, a U.S.-based contract development and manufacturing organization (CDMO) specializing in cell therapies, today announced the continued build-out of its Board of Directors, including the appointment of Ted Dolan and Soyoung Park. They join Jin Pyun, Harry S. Rathore, Ph.D., and Yonghoon Kim, alongside Chairman and CEO Syed T. Husain, as part of a deliberate effort to align the company's governance with its next phase of growth. Over the past year, Made Scientific has assembled a Board with deep experience spanning CD

    4/30/26 11:47:00 AM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Cue Health Announces Strategic Actions to Position Company for Next Stage

    Clint Sever Appointed CEO Board Appoints Two Strategic Advisors Who Bring Significant Industry Expertise Cue Health Inc. ("Cue" or the "Company") (NASDAQ:HLTH), a healthcare technology company, today announced strategic actions implemented by its Board of Directors (the "Board") to best position the Company for its next stage: Clint Sever, co-founder and current Chief Product Officer, has been appointed CEO, effective immediately. Sever succeeds Ayub Khattak, who is stepping down as Chief Executive Officer, President, and Chairman. Khattak will remain a member of the Board of Directors. The Board has appointed two strategic advisors, who have specific subject matter expertise in i

    3/20/24 5:21:00 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Cue Health Announces Appointment of Rishi Reddy to Board of Directors

    Cue Health (NASDAQ:HLTH), a healthcare technology company, today announced it entered into a cooperation agreement (the "Cooperation Agreement") with Tarsadia Investments ("Tarsadia"), and appointed Rishi Reddy to its board of directors (the "Board"), effective immediately. Mr. Reddy is a Managing Director at Tarsadia, where he leads the firm's venture and growth equity strategy. He was previously an Observer on Cue's Board of Directors from April 2018 to September 2021. In addition, the Board intends to commence a process to add an additional highly qualified, independent director to the Board. "Cue remains focused on creating value for all of its stakeholders," said Ayub Khattak, Chairm

    2/16/24 5:00:00 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Cue Health downgraded by BTIG Research

    BTIG Research downgraded Cue Health from Buy to Neutral

    3/14/24 7:38:37 AM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    BTIG Research initiated coverage on Cue Health with a new price target

    BTIG Research initiated coverage of Cue Health with a rating of Buy and set a new price target of $18.00

    10/19/21 9:45:18 AM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Morgan Stanley initiated coverage on Cue Health with a new price target

    Morgan Stanley initiated coverage of Cue Health with a rating of Equal-Weight and set a new price target of $12.00

    10/19/21 8:30:49 AM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $HLTH
    SEC Filings

    View All

    Cue Health Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Cue Health Inc. (0001628945) (Filer)

    5/28/24 5:02:54 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Cue Health Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

    8-K - Cue Health Inc. (0001628945) (Filer)

    5/16/24 4:20:43 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form NT 10-Q filed by Cue Health Inc.

    NT 10-Q - Cue Health Inc. (0001628945) (Filer)

    5/16/24 4:17:26 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $HLTH
    Financials

    Live finance-specific insights

    View All

    Cue Health to Announce First Quarter Financial Results

    Cue Health Inc. ("Cue") (NASDAQ:HLTH), a healthcare technology company, announced today that it will release its first quarter 2024 financial results on Monday, May 13, 2024. The company will not be hosting a conference call. About Cue Health Cue Health Inc. (NASDAQ:HLTH) is a healthcare technology company that uses diagnostic-enabled care to empower people to live their healthiest lives. Cue's platform offers individuals and healthcare providers convenient and personalized access to lab-quality diagnostic tests at home and at the point-of-care, as well as on-demand telehealth consultations and treatment options for a wide range of health and wellness needs. Cue's customers include fede

    4/29/24 4:01:00 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Cue Health Reports Fourth Quarter 2023 Financial Results

    Cue Health Inc. ("Cue" or the "Company") (NASDAQ:HLTH), a healthcare technology company, today reported financial results for the fourth quarter and full-year 2023. Recent Highlights Reported fourth quarter total revenue of $18.8 million. Full-year 2023 total revenue was $70.9 million Submitted additional clinical samples and stability data for RSV to the FDA in support of de novo submission Submitted additional clinical samples and gathering additional stability data for Flu A/B to the FDA in support of de novo submission In late stage development of Herpes + Mpox Multiplex Molecular Test with plan to submit for EUA in 2Q24 Executed cost reduction plans, resulting in cash

    3/13/24 4:01:00 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Cue Health to Announce Fourth Quarter and Full Year 2023 Financial Results

    Cue Health Inc. ("Cue") (NASDAQ:HLTH), a healthcare technology company, announced today that it will release its fourth quarter and full year 2023 financial results on Wednesday, March 13, 2024. In conjunction with the release, Cue will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique personal PIN that can be used to join the call. The live webinar of the call may be accessed by visiting the Events

    2/28/24 4:01:00 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $HLTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Cue Health Inc. (Amendment)

    SC 13D/A - Cue Health Inc. (0001628945) (Subject)

    5/17/24 3:21:32 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13D/A filed by Cue Health Inc. (Amendment)

    SC 13D/A - Cue Health Inc. (0001628945) (Subject)

    2/21/24 5:00:19 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Cue Health Inc. (Amendment)

    SC 13G/A - Cue Health Inc. (0001628945) (Subject)

    2/14/24 5:09:58 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials